SAN FRANCISCO, CALIF., May 19, 2017 – Don Manning, chief medical officer, will present at the 2017 BIO International Convention in San Diego, CA. Dr. Manning will present an overview of the Adynxx transcription factor decoy technology and introduce AYX1, Adynxx’s lead program for the reduction of acute pain and prevention of chronic pain. The presentation will take place at 11:30am on Wednesday June 21st in the San Diego Convention Center, Company Presentation Theater #3.
Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery and resolving established chronic pain conditions. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.
Adynxx’s lead compound, AYX1, is an investigational drug designed to reduce acute post-surgical pain and prevent the transition to persistent or chronic pain with a single administration at the time of surgery. Adynxx has successfully demonstrated clinical efficacy in two Phase 2 clinical studies of AYX1 and is currently enrolling a final Phase 2 study to prepare for Phase 3 initiation in 2018. Additional AYX drug candidate compounds designed to address a range of intractable neuropathic and inflammatory pain syndromes are also in active development.